Biogen's high-risk bet on Alzheimer's a potential game changer
This article was originally published in Scrip
Interim data from an early study in Alzheimer's disease patients being treated with Biogen Idec's aducanumab (previously known as BIIB037) could be a breakthrough in the field – having major implications for the company, as well as for patients.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.